Given Imaging's M2A to be Reimbursed by Three New Payors

First policy covering suspected Crohn’s disease and small bowel tumors issued

1/21/2003 - ATLANTA GA -- Given Imaging (NASDAQ:GIVN) announced today that three new payors, Blue Cross of California, Blue Cross & Blue Shield of Rhode Island Medicare and HGSAdministrators which is Highmark of Pennsylvania’s government business unit, have established coverage policies for the M2A capsule endoscope. HGSAdministrators’ policy is the first to also cover the M2A procedure for patients who demonstrate symptoms of Crohn’s disease or small bowel tumors that can not be confirmed by other methods.

"These new policies and recent CMS decisions at the national level reflect the momentum capsule endoscopy is gaining in expanding reimbursement coverage," said Gavriel D. Meron, President and CEO of Given Imaging. "Allowing doctors to use capsule endoscopy to diagnose suspected Crohn’s disease can lead to earlier treatment for this difficult to diagnose condition, thus reducing unwarranted suffering for patients and costs to payors."

Blue Cross of California and its California affiliates have more than 6.8 million members. HGSAdministrators serves approximately 2 million Pennsylvanians with Medicare coverage and Blue Cross & Blue Shield of Rhode Island Medicare serves approximately 150,000 beneficiaries. These additional 9 million beneficiaries bring to approximately 47 million the total number of Americans who have reimbursable access to capsule endoscopy.

For additional information please see Given Imaging's reimbursement fact sheet at http://www.givenimaging.com/usa/reimbursement.asp. Editor's Note: This link is no longer active.

This press release contains forward-looking statements about Given Imaging, including projections about our business, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03